Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors

The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show, in multiple complementary models, that...

詳細記述

保存先:
書誌詳細
主要な著者: Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S., Pratilas, Christine A., Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V., Tadi, Madhavi, Rogers, Andrew, Repellin, Claire, Capelletti, Marzia, Maertens, Ophélia, Goetz, Eva M., Letai, Anthony, Garraway, Levi A., Lazzara, Matthew J., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477553/
https://ncbi.nlm.nih.gov/pubmed/22961667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0103
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料